 Jonathan Kaufman
Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Surgical Procedures | 11 | 2020 | 414 | 1.940 |
Why?
| | Intensive Care Units, Pediatric | 7 | 2020 | 148 | 1.870 |
Why?
| | Heart Defects, Congenital | 11 | 2020 | 683 | 1.590 |
Why?
| | Postoperative Complications | 9 | 2020 | 2122 | 1.020 |
Why?
| | Quality Improvement | 3 | 2018 | 944 | 0.980 |
Why?
| | Hyponatremia | 2 | 2016 | 37 | 0.960 |
Why?
| | Enteral Nutrition | 7 | 2020 | 157 | 0.800 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 1356 | 0.730 |
Why?
| | Intensive Care Units | 5 | 2020 | 614 | 0.710 |
Why?
| | Multiple Myeloma | 4 | 2022 | 98 | 0.690 |
Why?
| | Infant, Newborn | 23 | 2020 | 5038 | 0.690 |
Why?
| | Airway Extubation | 1 | 2020 | 43 | 0.660 |
Why?
| | Vascular Access Devices | 1 | 2018 | 24 | 0.590 |
Why?
| | Cardiac Care Facilities | 1 | 2017 | 13 | 0.590 |
Why?
| | Postoperative Care | 3 | 2014 | 223 | 0.580 |
Why?
| | Heart Diseases | 3 | 2016 | 329 | 0.560 |
Why?
| | Hypernatremia | 1 | 2016 | 7 | 0.550 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2014 | 114 | 0.510 |
Why?
| | Stem Cell Transplantation | 2 | 2022 | 148 | 0.510 |
Why?
| | Vasodilator Agents | 3 | 2013 | 302 | 0.510 |
Why?
| | Infant | 17 | 2020 | 7943 | 0.490 |
Why?
| | Boronic Acids | 3 | 2014 | 33 | 0.470 |
Why?
| | Infant, Premature | 3 | 2020 | 478 | 0.470 |
Why?
| | Tachycardia | 2 | 2014 | 50 | 0.470 |
Why?
| | Pyrazines | 3 | 2014 | 71 | 0.460 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 44 | 0.460 |
Why?
| | Blood Chemical Analysis | 1 | 2014 | 90 | 0.450 |
Why?
| | Parenteral Nutrition | 1 | 2015 | 96 | 0.450 |
Why?
| | Milrinone | 1 | 2013 | 24 | 0.440 |
Why?
| | Norwood Procedures | 1 | 2013 | 22 | 0.440 |
Why?
| | Calcitonin | 1 | 2013 | 23 | 0.430 |
Why?
| | Critical Illness | 2 | 2016 | 640 | 0.430 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2013 | 29 | 0.430 |
Why?
| | Dexamethasone | 5 | 2022 | 316 | 0.430 |
Why?
| | Prilocaine | 1 | 2013 | 3 | 0.430 |
Why?
| | Methemoglobinemia | 1 | 2013 | 13 | 0.420 |
Why?
| | Thrombosis | 2 | 2018 | 295 | 0.420 |
Why?
| | Lidocaine | 1 | 2013 | 40 | 0.420 |
Why?
| | Tidal Volume | 1 | 2013 | 75 | 0.410 |
Why?
| | Nutritional Status | 1 | 2015 | 286 | 0.410 |
Why?
| | Protein Precursors | 1 | 2013 | 119 | 0.410 |
Why?
| | Masks | 1 | 2013 | 46 | 0.400 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2013 | 51 | 0.400 |
Why?
| | Anesthetics, Local | 1 | 2013 | 81 | 0.400 |
Why?
| | Bronchiolitis | 1 | 2013 | 81 | 0.400 |
Why?
| | Cardiac Output, Low | 1 | 2012 | 64 | 0.390 |
Why?
| | Weight Gain | 1 | 2015 | 453 | 0.380 |
Why?
| | Length of Stay | 6 | 2018 | 957 | 0.380 |
Why?
| | Cardiotonic Agents | 1 | 2012 | 121 | 0.380 |
Why?
| | Catheter Obstruction | 1 | 2011 | 3 | 0.370 |
Why?
| | C-Reactive Protein | 1 | 2013 | 362 | 0.370 |
Why?
| | Retrospective Studies | 17 | 2020 | 12521 | 0.360 |
Why?
| | Chylothorax | 1 | 2010 | 11 | 0.360 |
Why?
| | Octreotide | 1 | 2010 | 25 | 0.360 |
Why?
| | Seizures | 1 | 2013 | 337 | 0.340 |
Why?
| | Heart Rate | 1 | 2013 | 710 | 0.340 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 57 | 0.340 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2012 | 241 | 0.340 |
Why?
| | Catheterization, Central Venous | 1 | 2011 | 83 | 0.340 |
Why?
| | Gastrostomy | 2 | 2020 | 89 | 0.330 |
Why?
| | Heparin | 1 | 2011 | 225 | 0.330 |
Why?
| | Abnormalities, Multiple | 1 | 2011 | 176 | 0.330 |
Why?
| | Palliative Care | 1 | 2015 | 641 | 0.310 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2015 | 70 | 0.310 |
Why?
| | Vasculitis | 1 | 2008 | 65 | 0.300 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 4 | 2013 | 82 | 0.300 |
Why?
| | Humans | 40 | 2022 | 114045 | 0.290 |
Why?
| | Male | 30 | 2020 | 55396 | 0.290 |
Why?
| | Sepsis | 1 | 2013 | 507 | 0.290 |
Why?
| | Colorado | 5 | 2020 | 4090 | 0.280 |
Why?
| | Critical Care | 1 | 2011 | 472 | 0.280 |
Why?
| | Bortezomib | 6 | 2022 | 41 | 0.270 |
Why?
| | Female | 29 | 2020 | 59324 | 0.270 |
Why?
| | Respiration, Artificial | 3 | 2020 | 528 | 0.260 |
Why?
| | Biomarkers | 3 | 2016 | 3397 | 0.240 |
Why?
| | Incidence | 5 | 2020 | 2314 | 0.240 |
Why?
| | Follow-Up Studies | 7 | 2020 | 4392 | 0.230 |
Why?
| | Intubation, Intratracheal | 2 | 2020 | 214 | 0.220 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2018 | 27 | 0.220 |
Why?
| | Child, Preschool | 11 | 2019 | 9114 | 0.220 |
Why?
| | Intubation, Gastrointestinal | 2 | 2020 | 54 | 0.220 |
Why?
| | Acute Kidney Injury | 4 | 2020 | 637 | 0.220 |
Why?
| | Cohort Studies | 5 | 2019 | 4883 | 0.210 |
Why?
| | Prospective Studies | 6 | 2018 | 6195 | 0.210 |
Why?
| | Maintenance Chemotherapy | 1 | 2022 | 22 | 0.200 |
Why?
| | Child | 11 | 2020 | 18401 | 0.200 |
Why?
| | Disease-Free Survival | 5 | 2022 | 618 | 0.200 |
Why?
| | Risk Factors | 8 | 2020 | 8614 | 0.190 |
Why?
| | Cyclophosphamide | 5 | 2020 | 214 | 0.190 |
Why?
| | Drug Administration Schedule | 6 | 2014 | 714 | 0.190 |
Why?
| | Cyanosis | 1 | 2020 | 15 | 0.180 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2020 | 4 | 0.180 |
Why?
| | Time Factors | 6 | 2013 | 6077 | 0.170 |
Why?
| | Rituximab | 5 | 2015 | 148 | 0.170 |
Why?
| | Analysis of Variance | 2 | 2013 | 1218 | 0.170 |
Why?
| | Fundoplication | 1 | 2020 | 51 | 0.170 |
Why?
| | Treatment Outcome | 10 | 2020 | 9049 | 0.170 |
Why?
| | Calcaneus | 1 | 2019 | 57 | 0.160 |
Why?
| | Ketorolac | 1 | 2018 | 16 | 0.160 |
Why?
| | Platelet Aggregation | 1 | 2018 | 90 | 0.150 |
Why?
| | Gastroesophageal Reflux | 1 | 2020 | 229 | 0.150 |
Why?
| | Catheters, Indwelling | 1 | 2018 | 74 | 0.140 |
Why?
| | Combined Modality Therapy | 2 | 2010 | 1117 | 0.140 |
Why?
| | Morphine | 1 | 2018 | 121 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2014 | 1836 | 0.140 |
Why?
| | Diuretics | 1 | 2016 | 64 | 0.130 |
Why?
| | Pain, Postoperative | 1 | 2018 | 190 | 0.130 |
Why?
| | Prognosis | 5 | 2018 | 3315 | 0.130 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2016 | 47 | 0.130 |
Why?
| | Sodium | 1 | 2016 | 184 | 0.130 |
Why?
| | Bone Density | 1 | 2019 | 432 | 0.130 |
Why?
| | Lymphoma, Follicular | 2 | 2015 | 34 | 0.130 |
Why?
| | Logistic Models | 4 | 2014 | 1829 | 0.120 |
Why?
| | Gestational Age | 2 | 2020 | 761 | 0.120 |
Why?
| | Hypertension, Pulmonary | 1 | 2005 | 1736 | 0.120 |
Why?
| | Heart | 1 | 2018 | 613 | 0.110 |
Why?
| | Remission Induction | 2 | 2014 | 233 | 0.110 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2013 | 31 | 0.110 |
Why?
| | Pediatrics | 2 | 2011 | 982 | 0.110 |
Why?
| | Lung | 1 | 2005 | 3521 | 0.110 |
Why?
| | Port-Wine Stain | 1 | 2013 | 2 | 0.110 |
Why?
| | Down Syndrome | 1 | 2018 | 335 | 0.110 |
Why?
| | Delivery Rooms | 1 | 2013 | 6 | 0.110 |
Why?
| | Liver Function Tests | 1 | 2013 | 103 | 0.110 |
Why?
| | Administration, Topical | 1 | 2013 | 137 | 0.100 |
Why?
| | Survival Rate | 2 | 2013 | 1638 | 0.100 |
Why?
| | Equipment Failure | 1 | 2013 | 107 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 384 | 0.100 |
Why?
| | Intubation | 1 | 2012 | 3 | 0.100 |
Why?
| | Health Care Surveys | 2 | 2011 | 541 | 0.100 |
Why?
| | Australia | 1 | 2013 | 205 | 0.100 |
Why?
| | Respiration | 1 | 2013 | 180 | 0.100 |
Why?
| | Pentobarbital | 1 | 2011 | 16 | 0.100 |
Why?
| | Patient Admission | 1 | 2013 | 175 | 0.100 |
Why?
| | Status Epilepticus | 1 | 2011 | 32 | 0.100 |
Why?
| | Vein of Galen Malformations | 1 | 2011 | 2 | 0.090 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2011 | 20 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 522 | 0.090 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 19 | 0.090 |
Why?
| | Heterocyclic Compounds | 1 | 2011 | 18 | 0.090 |
Why?
| | Professional Practice | 1 | 2011 | 63 | 0.090 |
Why?
| | Linear Models | 1 | 2013 | 768 | 0.090 |
Why?
| | Analgesics, Opioid | 1 | 2018 | 771 | 0.090 |
Why?
| | Receptors, CXCR4 | 1 | 2011 | 78 | 0.090 |
Why?
| | Airway Obstruction | 1 | 2013 | 160 | 0.090 |
Why?
| | Lymphoma, B-Cell | 1 | 2012 | 87 | 0.090 |
Why?
| | Nutritional Support | 1 | 2010 | 27 | 0.090 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2011 | 51 | 0.090 |
Why?
| | Anesthetics, Intravenous | 1 | 2010 | 27 | 0.090 |
Why?
| | ROC Curve | 1 | 2012 | 441 | 0.090 |
Why?
| | Electrocardiography | 1 | 2013 | 561 | 0.090 |
Why?
| | Hypnotics and Sedatives | 1 | 2011 | 133 | 0.090 |
Why?
| | Chemoprevention | 1 | 2011 | 87 | 0.090 |
Why?
| | Ventilator Weaning | 1 | 2010 | 33 | 0.090 |
Why?
| | Diet, Fat-Restricted | 1 | 2010 | 73 | 0.090 |
Why?
| | Propofol | 1 | 2010 | 43 | 0.090 |
Why?
| | Salvage Therapy | 1 | 2011 | 127 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2011 | 281 | 0.090 |
Why?
| | Thalidomide | 1 | 2010 | 28 | 0.090 |
Why?
| | Aortic Coarctation | 1 | 2011 | 70 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 347 | 0.090 |
Why?
| | Lymphoma | 1 | 2011 | 176 | 0.090 |
Why?
| | Birth Weight | 1 | 2013 | 439 | 0.090 |
Why?
| | Drainage | 1 | 2010 | 145 | 0.090 |
Why?
| | Infusions, Intravenous | 3 | 2018 | 370 | 0.080 |
Why?
| | Kinetics | 1 | 2013 | 1547 | 0.080 |
Why?
| | Device Removal | 1 | 2010 | 123 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2014 | 850 | 0.080 |
Why?
| | Kidney | 1 | 2016 | 1182 | 0.080 |
Why?
| | Plasmapheresis | 1 | 2008 | 21 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1331 | 0.080 |
Why?
| | Alprostadil | 1 | 2008 | 31 | 0.080 |
Why?
| | High-Frequency Ventilation | 1 | 2008 | 41 | 0.080 |
Why?
| | Antibodies, Monoclonal | 2 | 2020 | 1257 | 0.080 |
Why?
| | Vincristine | 3 | 2015 | 98 | 0.080 |
Why?
| | Adolescent | 8 | 2018 | 17800 | 0.080 |
Why?
| | Adult | 9 | 2022 | 30375 | 0.080 |
Why?
| | Renal Replacement Therapy | 1 | 2008 | 66 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 660 | 0.080 |
Why?
| | Aged | 7 | 2020 | 18969 | 0.080 |
Why?
| | Neoadjuvant Therapy | 1 | 2010 | 305 | 0.080 |
Why?
| | Middle Aged | 8 | 2020 | 26605 | 0.070 |
Why?
| | Doxorubicin | 3 | 2015 | 286 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 813 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1791 | 0.070 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 175 | 0.070 |
Why?
| | Patient Readmission | 1 | 2012 | 607 | 0.070 |
Why?
| | Anticoagulants | 1 | 2011 | 547 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2010 | 673 | 0.070 |
Why?
| | Immunologic Factors | 1 | 2008 | 217 | 0.070 |
Why?
| | Preoperative Care | 1 | 2008 | 319 | 0.070 |
Why?
| | HIV Infections | 1 | 2019 | 2453 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 493 | 0.060 |
Why?
| | rho-Associated Kinases | 1 | 2005 | 80 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 641 | 0.060 |
Why?
| | Hemorrhage | 1 | 2008 | 600 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2011 | 970 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 388 | 0.050 |
Why?
| | Maximum Tolerated Dose | 2 | 2014 | 183 | 0.050 |
Why?
| | Prednisone | 2 | 2015 | 229 | 0.050 |
Why?
| | Melphalan | 1 | 2022 | 29 | 0.050 |
Why?
| | Lung Diseases | 1 | 2008 | 690 | 0.050 |
Why?
| | Thrombocytopenia | 2 | 2015 | 177 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 3003 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2537 | 0.050 |
Why?
| | Viscera | 1 | 2020 | 15 | 0.040 |
Why?
| | Immunoglobulin Light Chains | 1 | 2020 | 36 | 0.040 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2020 | 72 | 0.040 |
Why?
| | Cellulitis | 1 | 2020 | 45 | 0.040 |
Why?
| | Nervous System | 1 | 2020 | 63 | 0.040 |
Why?
| | Heart Failure | 1 | 2012 | 1958 | 0.040 |
Why?
| | South Africa | 1 | 2019 | 160 | 0.040 |
Why?
| | Cardiopulmonary Bypass | 1 | 2020 | 174 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 288 | 0.040 |
Why?
| | Thrombelastography | 1 | 2018 | 129 | 0.040 |
Why?
| | Rats | 1 | 2005 | 4913 | 0.040 |
Why?
| | Anti-Retroviral Agents | 1 | 2019 | 207 | 0.040 |
Why?
| | Infant Mortality | 1 | 2018 | 91 | 0.040 |
Why?
| | Ultrasonography | 1 | 2019 | 635 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1447 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 296 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2371 | 0.030 |
Why?
| | Pneumonia | 1 | 2020 | 563 | 0.030 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2015 | 120 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2014 | 80 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 182 | 0.030 |
Why?
| | Hyperbilirubinemia | 1 | 2013 | 14 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2384 | 0.030 |
Why?
| | Liver Failure | 1 | 2013 | 73 | 0.030 |
Why?
| | Indoles | 1 | 2014 | 300 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 725 | 0.020 |
Why?
| | Neutropenia | 1 | 2013 | 123 | 0.020 |
Why?
| | Ventricular Function, Right | 1 | 2014 | 256 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2011 | 28 | 0.020 |
Why?
| | Neural Conduction | 1 | 2012 | 78 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2012 | 116 | 0.020 |
Why?
| | Cytarabine | 1 | 2011 | 51 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 1875 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2011 | 113 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2958 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1206 | 0.020 |
Why?
| | Prostaglandins | 1 | 2011 | 77 | 0.020 |
Why?
| | Benzylamines | 1 | 2011 | 39 | 0.020 |
Why?
| | Mouth | 1 | 2011 | 69 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2013 | 227 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2011 | 88 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2011 | 70 | 0.020 |
Why?
| | Blood Component Removal | 1 | 2011 | 26 | 0.020 |
Why?
| | Internationality | 1 | 2011 | 143 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1656 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 925 | 0.020 |
Why?
| | Electroencephalography | 1 | 2011 | 359 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6306 | 0.020 |
Why?
| | Animals | 2 | 2010 | 31565 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 544 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 338 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2012 | 773 | 0.020 |
Why?
| | Internet | 1 | 2011 | 591 | 0.020 |
Why?
| | Young Adult | 2 | 2011 | 10444 | 0.020 |
Why?
| | Liver | 1 | 2013 | 1633 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 4680 | 0.010 |
Why?
| | United States | 1 | 2011 | 12137 | 0.010 |
Why?
| | Mice | 1 | 2010 | 14843 | 0.010 |
Why?
|
|
Kaufman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|